Drug intelligence / Profile preview

UMN-104

Development stage: Unknown
Lead developer: University of Minnesota
Modality: Vaccines & Immunotherapeutics

Overview

UMN-104 is a vaccine candidate under development by UMN. Pharma, targeting norovirus infection. As a vaccine, its mechanism of action involves stimulating the body's immune system to recognize and produce antibodies against specific norovirus antigens. This induced immune response aims to provide protection against future exposure to the norovirus, thereby preventing or mitigating the severity of norovirus-induced gastroenteritis.

Targets

Norovirus VP1

Beyond the preview

Go deeper on UMN-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UMN-104.

Explore the full profile